An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors

Cancer Gene Therapy

Volumn 16, Issue 1, 2009, Pages 33-43

  Lei, N ^a   Shen, F B ^b   Chang, J H ^c   Wang, L ^a   Li, H ^d   Yang, C ^d   Li, J ^c,g   Yu, D C ^d,e,f  

^a SICHUAN UNIVERSITY   (China)

^b CHENGDU MEDICAL COLLEGE   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^d Chengdu Kanghong Biotechnology Co Ltd   (China)

^e ZHEJIANG UNIVERSITY   (China)

^f ZHEJIANG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^g FUDAN UNIVERSITY   (China)

Author keywords

Adenoviridae; E2F transcription factors; Promoter regions (genetics); Telomerase; Therapeutic research

Indexed keywords

DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ONCOLYTIC ADENOVIRUS; ONCOLYTIC ADENOVIRUS KH920; ONCOLYTIC ADENOVIRUS TOA02; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; DENDRITIC CELL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SELECTIVITY; FEMALE; GENE INSERTION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MACROPHAGE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROMOTER REGION; SOLID TUMOR; TUMOR XENOGRAFT; WILD TYPE;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RESPONSE ELEMENTS; TELOMERASE;

ADENOVIRIDAE; MUS; MUS MUSCULUS;

EID: 57649125119     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.46     Document Type: Article

References (39)

1. Ko D, Hawkins L, Yu DC. Development of transcriptionally regulated oncolytic adenoviruses. Oncogene 2005; 24: 7763-7774.
2. Li Y, Yu DC , Chen Y, Amin P, Zhang H, Nguyen N et al. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res 2001; 61:6428-6436.
3. Yu DC, Chen Y, Seng M, Dilley J, Henderson DR. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 1999; 59: 4200-4203.
4. Yu DC, Chen Y, Dilley J, Li Y, Embry M, Zhang H et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 2001; 61: 517-525.
5. Dilley J, Reddy S, Ko D, Nguyen N, Rojas G, Working P et al. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity. Cancer Gene Ther 2005; 12: 715-722.
6. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33: 787-791.
7. Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, Teraishi F et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 2004; 10(1 Part 1): 285-292.
8. Davis JJ, Wang L, Dong F, Zhang L, Guo W, Teraishi F et al. Oncolysis and suppression of tumor growth by a GFP-expressing oncolytic adenovirus controlled by an hTERT and CMV hybrid promoter. Cancer Gene Ther 2006; 13: 720-723. E-pub 2006 Feb 17.
9. Groot-Wassink T, Aboagye EO, Wang Y, Lemoine NR, Keith WN, Vassaux G. Noninvasive imaging of the transcriptional activities of human telomerase promoter fragments in mice. Cancer Res 2004; 64: 4906-4911.
10. Bilsland AE, Anderson CJ, Fletcher-Monaghan AJ, McGregor F, Evans TR, Ganly I et al. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene 2003; 22: 370-380.
11. Bilsland AE, Merron A, Vassaux G, Keith WN. Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses. Cancer Res 2007; 67: 1299-1307.
12. Kim E, Kim JH, Shin HY, Lee H, Yang JM, Kim J et al. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther 2003; 14: 1415-1428.
13. Bortolanza S, Qian C, Kramer MG, Gomar C, Prieto J, Farinati F et al. An oncolytic adenovirus controlled by a modified telomerase promoter is attenuated in telomerase-negative cells, but shows reduced activity in cancer cells. J Mol Med 2005; 83: 736-747.
14. Ramesh N, Ge Y, Ennist DL, Zhu M, Mina M, Ganesh S et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor-armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res 2006; 12: 305-313.
15. Neuman E, Flemington EK, Sellers WR, Kaelin Jr WG. Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter. Mol Cell Biol 1994; 14: 6607-6615.
16. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
17. Li Y, Idamakanti N, Arroyo T, Thorne S, Reid T, Nichols S et al. Dual promoter-controlled oncolytic adenovirus CG5757 has strong tumor selectivity and significant antitumor efficacy in preclinical models. Clin Cancer Res 2005; 11(24 Part 1): 8845-8855.
18. Fu B, Quintero J, Baker CC. Keratinocyte growth conditions modulate telomerase expression, senescence, and immortalization by human papillomavirus type 16 E6 and E7 oncogenes. Cancer Res 2003; 63: 7815-7824.
19. Liu X, Clements A, Zhao K, Marmorstein R. Structure of the human Papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J Biol Chem 2006; 281: 578-586.
20. Li Y, Chen Y, Dilley J, Arroyo T, Ko D, Working P et al. Carcinoembryonic antigen-producing cell-specific oncolytic adenovirus, OV798, for colorectal cancer therapy. Mol Cancer Ther 2003; 2: 1003-1009.
21. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70: 7498-7509.
22. Jakubczak JL, Ryan P, Gorziglia M, Clarke L, Hawkins LK, Hay C et al. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res 2003; 63: 1490-1499.
23. Bristol JA, Zhu M, Ji H, Mina M, Xie Y, Clarke L et al. In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF. Mol Ther 2003; 7: 755-764.
24. Melillo RM, Helin K, Lowy DR, Schiller JT. Positive and negative regulation of cell proliferation by E2F-1: influence of protein level and human papillomavirus oncoproteins. Mol Cell Biol 1994; 14: 8241-8249.
25. Hallden G, Hill R, Wang Y, Anand A, Liu TC, Lemoine NR et al. Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Mol Ther 2003; 8: 412-424.
26. Scheinecker C, McHugh R, Shevach EM, Germain RN. Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. J Exp Med 2002; 196: 1079-1090.
27. Wirth T, Kuhnel F, Kubicka S. Telomerase-dependent gene therapy. Curr Mol Med 2005; 5: 243-251.
28. Hahn WC, Meyerson M. Telomerase activation, cellular immortalization and cancer. Ann Med 2001; 33: 123-129.
29. Zhang B, Chen W, Roman A. The E7 proteins of low- and high-risk human papillomaviruses share the ability to target the pRB family member p130 for degradation. Proc Natl Acad Sci USA 2006; 103: 437-442.
30. Bauerschmitz GJ, Guse K, Kanerva A, Menzel A, Herrmann I, Desmond RA et al. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther 2006; 14: 164-174.
31. Rocconi RP, Zhu ZB, Stoff-Khalili M, Rivera AA, Lu B, Wang M et al. Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd). Gynecol Oncol 2007; 105: 113-121.
32. Hernandez-Alcoceba R, Pihalja M, Qian D, Clarke MF. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum Gene Ther 2002; 13: 1737-1750.
33. Masutomi K, Yu EY, Khurts S, Ben-Porath I, Currier JL, Metz GB et al. Telomerase maintains telomere structure in normal human cells. Cell 2003; 114: 241-253.
34. Alonso MM, Fueyo J, Shay JW, Aldape KD, Jiang H, Lee OH et al. Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance. J Natl Cancer Inst 2005; 97: 1589-1600.
35. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 2006; 14: 107-117.
36. Dessureault S, Noyes D, Lee D, Dunn M, Janssen W, Cantor A et al. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing Bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Ann Surg Oncol 2007; 14: 869-884.
37. Hege KM, Jooss K, Pardoll D. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int Rev Immunol 2006; 25: 321-352.
38. Horikawa I, Chiang YJ, Patterson T, Feigenbaum L, Leem SH, Michishita E et al. Differential cis-regulation of human versus mouse TERT gene expression in vivo: identification of a human-specific repressive element. Proc Natl Acad Sci USA 2005; 102: 18437-18442.
39. Maione D, De lla Rocca C, G iannetti P, D'Arrigo R, Liberatoscioli L, Franl in LL et al. An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus. Proc Natl Acad Sci USA 2001; 98: 5986-5991.